Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
8.71B | 8.35B | 7.12B | 6.22B | 5.71B | 4.36B | Gross Profit |
5.85B | 5.63B | 4.73B | 4.20B | 3.96B | 2.86B | EBIT |
2.46B | 2.35B | 1.77B | 1.21B | 1.82B | 773.60M | EBITDA |
2.95B | 2.81B | 2.17B | 1.94B | 2.13B | 1.33B | Net Income Common Stockholders |
2.48B | 2.32B | 1.80B | 1.32B | 1.70B | 1.06B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
4.51B | 4.01B | 5.22B | 6.74B | 8.62B | 6.87B | Total Assets |
19.22B | 18.74B | 15.44B | 12.97B | 13.55B | 11.17B | Total Debt |
0.00 | 146.00M | 89.80M | 93.80M | 87.00M | 79.90M | Net Debt |
-2.57B | -1.88B | -2.66B | -1.49B | -1.20B | -1.54B | Total Liabilities |
2.01B | 2.21B | 2.04B | 1.86B | 1.60B | 1.41B | Stockholders Equity |
17.11B | 16.43B | 13.31B | 11.11B | 11.95B | 9.76B |
Cash Flow | Free Cash Flow | ||||
1.75B | 1.30B | 749.60M | 958.40M | 1.74B | 1.14B | Operating Cash Flow |
2.73B | 2.42B | 1.81B | 1.49B | 2.09B | 1.48B | Investing Cash Flow |
-2.93B | -3.27B | -360.10M | 1.37B | -2.46B | -940.60M | Financing Cash Flow |
-38.20M | 150.90M | -287.60M | -2.57B | 43.00M | -85.70M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
85 Outperform | $37.05B | 28.37 | 25.81% | 0.84% | 9.54% | 37.23% | |
73 Outperform | $189.82B | 76.63 | 15.94% | ― | 19.08% | 23.13% | |
70 Outperform | $14.52B | 27.27 | 11.77% | ― | 1.66% | 21.95% | |
69 Neutral | $14.50B | 34.64 | 5.15% | ― | 6.88% | 21.11% | |
68 Neutral | $49.50B | 32.96 | 5.97% | 2.41% | 5.84% | 15.12% | |
60 Neutral | $16.11B | 136.07 | -8.96% | 2.17% | -20.17% | -138.32% | |
54 Neutral | $5.38B | 3.31 | -45.11% | 3.29% | 16.82% | 0.04% |
On May 14, 2025, Intuitive Surgical‘s Board of Directors appointed David J. Rosa as the new Chief Executive Officer, effective July 1, 2025. Rosa, who has been with the company for 29 years, will replace Gary S. Guthart, who will transition to Executive Chair of the Board. This leadership change is part of the company’s strategic succession planning to drive future growth. The announcement highlights Rosa’s extensive experience and contributions to Intuitive’s strategy and product development, positioning him as the right leader to continue advancing the company’s mission and expanding its global footprint.
The most recent analyst rating on (ISRG) stock is a Buy with a $525.00 price target. To see the full list of analyst forecasts on Intuitive Surgical stock, see the ISRG Stock Forecast page.
On May 1, 2025, Intuitive Surgical‘s stockholders approved several proposals at the annual meeting, including the amendment and restatement of the 2010 Incentive Award Plan, which increases the number of shares reserved for issuance and extends the plan’s term. Additionally, the company announced an increase in its stock repurchase program to $4.0 billion, indicating a strategic move to enhance shareholder value and manage its capital structure.